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Abstract This review discusses recent developments in
analytical methods available for the sensitive separation,
detection and structural characterization of heparin con-
taminants. The adulteration of raw heparin with over-
sulfated chondroitin sulfate (OSCS) in 2007–2008 spawned
a global crisis resulting in extensive revisions to the
pharmacopeia monographs on heparin and prompting the
FDA to recommend the development of additional physi-
cochemical methods for the analysis of heparin purity. The
analytical chemistry community quickly responded to this
challenge, developing a wide variety of innovative
approaches, several of which are reported in this special
issue. This review provides an overview of methods of
heparin isolation and digestion, discusses known heparin
contaminants, including OSCS, and summarizes recent
publications on heparin impurity analysis using sensors,
near-IR, Raman, and NMR spectroscopy, as well as
electrophoretic and chromatographic separations.
Keywords Contamination . Impurity . Heparin . NMR .
OSCS . Adulteration
Introduction
The scope of this critical review is to summarize and
discuss the recent analytical developments in the exploding
field of heparin impurity analysis a little over two years
after the intentional contamination of pharmaceutical
heparin with oversulfated chondroitin sulfate (OSCS) [1].
In fall 2007 and early 2008 serious adverse events
associated with heparin administration were reported.
Acute, allergic-type reactions were observed among
patients undergoing hemodialysis and after intravenous
infusion of unfractionated heparin [2, 3]. This adulteration
made the news and put heparin, one of the oldest drugs,
into the limelight. The consequences of the concomitant
health crisis are known; contaminated heparin was associ-
ated with over 200 deaths around the world. Regulations
were subsequently revised to ensure drug safety, and
sweeping changes in the analytical methods required for
heparin quality assurance were simultaneously imple-
mented [4]. Following previous reviews on heparin analysis
[5] and the lessons learned from the recent crisis [6], this
paper reviews the latest analytical methods for heparin
impurity analysis and provides some future prospects.
Heparin is a member of the glycosaminoglycan (GAG)
family. It is a polydisperse mixture of sulfonated linear
polysaccharides consisting of 1-4 linked and variously
modified uronic acid and D-glucosamine repeating disac-
charide subunits (Fig. 1) [7]. Compared to other GAG
biopolymers, such as chondroitin sulfate, dermatan sulfate,
keratan sulfate and hyaluronic acid, heparin is structur-
ally the most complex polysaccharide. The uronic acid of
heparin may be either α-L-iduronic (IdoA) or β-D-
glucuronic acid (GlcA) and can be unsubstituted or
sulfonated at the 2-O position. The glucosamine residue
may be unmodified (GlcN), N-sulfonated (GlcNS) or N-
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acetylated (GlcNA), and can contain variable patterns of
O-sulfonation at the 3-O and 6-O positions. The major
disaccharide sequence of heparin is the trisulfonated L-
IdoA(2S)-D-GlcNS(6S), which comprises roughly 70% of
heparin from porcine intestinal mucosa [7, 8]. The related
GAG heparan sulfate is a proteoglycan component of
many cell-surface receptors and an integral part of the
extracellular matrix [9]. Although based on the same basic
disaccharide subunit, the sulfonate content of heparan
sulfate is lower than heparin, with a GlcNA to GlcNS ratio
of >3, and heparan sulfate has about twice the level of
glucuronic as iduronic acid. Consequently, a GAG
qualifies as heparin only if the content of N-sulfo groups
greatly exceeds that of N-acetyl groups and the concen-
tration of O-sulfo groups exceeds that of N-sulfonate [10].
Heparin is biosynthesized as a proteoglycan in a multistep
process involving various enzymes in the endoplasmatic
reticulum and the Golgi apparatus of the mast cells of
connective tissues [7, 9]. The microheterogeneous structure
of heparin arises during biosynthesis through reactions
catalyzed by N-deacetylase, N- and O-sulfotransferase and
epimerase enzymes. Heparin is stored together with hista-
mine and mast cell basic proteases in secretory granules and
released into the extracellular space upon immunoglobulin-
E-receptor stimulation [11, 12]. Heparin is involved in the
mediation of many biological functions, such as cell
differentiation, proliferation and migration, adhesion and
host–pathogen interactions, mainly through interactions with
basic amino acid rich motifs of proteins [13–16].
Despite its involvement in these various biological
processes, heparin is best known as an intravenous
anticoagulant. Heparin was introduced into medical practice
in the 1930s, so it is one of the oldest drugs currently in
widespread clinical use [17]. Heparin’s anticoagulant
activity is due to the binding of a unique pentasaccharide
sequence (as shown in Fig. 1) containing a 3-O-sulfo
moiety to the protease inhibitor antithrombin III, causing a
conformational change that increases the flexibility of its
reactive site loop and thus its binding affinities for thrombin
and factors IXa and Xa [18, 19].
The large-scale industrial production of pharmaceutical
heparin begins with its isolation from mainly porcine
intestinal mucosa or whole intestine. As the natural sources
of heparin are diverse and the production of raw heparin is
not under strict control, the variability in the chemical
profile of raw heparin is not surprising. Consequently, some
variability is retained in pharmaceutical-grade heparin, even
after well-regulated purification processes [6]. The molec-
ular weight of natural (unfractionated) heparin is in the
range of 5–40 kDa, although in the vast majority of
preparations the 12–15 kDa chains predominate. The main
drawback of heparin administration resides in the poor
predictability of coagulation parameters. To overcome this
limitation, low molecular weight heparins (LMWHs) were
introduced into clinical use [20]. A further success of the
clinical application of LMWHs resides in their enhanced
subcutaneous bioavailability and improved pharmacokinet-
ics [21]. LMWHs are manufactured from unfractionated
heparin by controlled depolymerization, resulting in aver-
age molecular weights of 4–6 kDa [22]. Among the
currently marketed LMWHs, tinzaparin is processed via
the digestion of heparin using heparin lyase enzyme, while
nadroparin and dalteparin are prepared by nitrous acid
depolymerization. Enoxaparin is prepared by benzylation
and alkaline hydrolysis, while ardeparin and cantaxarin are
produced by oxidative fragmentation of the parent poly-
saccharide using hydrogen peroxide and periodate, respec-
tively [23, 24].
Heparin impurities
Considering the animal source of pharmaceutical heparin,
the numbers of potential impurities are relatively large
compared with a wholly synthetic therapeutic agent. The
range of possible biological contaminants includes viruses,
bacterial endotoxins, transmissible spongiform encephalop-
athy (TSE) agents, lipids, proteins and DNA. During the
preparation of pharmaceutical-grade heparin from animal
tissues, impurities such as solvents, heavy metals and
extraneous cations can be introduced. However, the methods
employed to minimize the occurrence and to identify and/or
eliminate these contaminants are well established and listed
in guidelines and pharmacopoeias. The major challenge in
the analysis of heparin impurities is the detection and
identification of structurally related impurities.
The most prevalent impurity in heparin is dermatan
sulfate (DS) [25], also known as chondroitin sulfate B. The
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Fig. 1 The unique antithrombin III binding pentasaccharide sequence and repeating disaccharide units of heparin. (R1 = H, SO3
−; R2 = H, SO3
−;
R3 = H, acetyl, SO3
− )
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building block of DS is a disaccharide comprised of 1,3-
linked N-acetyl galactosamine (GalN) and a uronic acid
residue, connected via 1,4 linkages to form the polymer. DS
is composed of three possible uronic acid (GlcA, IdoA or
IdoA2S) and four possible hexosamine (GalNAc, Gal-
NAc4S, GalNAc6S or GalNAc4S6S) building blocks. The
presence of iduronic acid in DS distinguishes it from
chrondroitin sulfate A and C and likens it to heparin and
HS [26]. DS has a lower negative charge density overall
compared to heparin. A common natural contaminant, DS
is present at levels of 1–7% in heparin API, but has no
proven biological activity that influences the anticoagula-
tion effect of heparin.
The chondroitin sulfate class of GAGs is comprised of
1,3-linked GlcA and GalN residues. The pattern of
sulfonation helps to classify the GAGs into CSA
(GalNAc4S), CSC (GalNAc6S), CSD (GlcA2S and
GalNAc6S), and CSE (GalNAc4S6S). The terms highly
or fully sulfated chondroitin sulfate (FSCS) refer to a
naturally occurring sequence bearing three sulfonates per
disaccharide unit. However, “oversulfated chondroitin
sulfate” (OSCS) is a semisynthetic compound containing
four sulfonate groups per building block [1, 27]. The
structural differences between DS, CS, and OSCS are
illustrated in Fig. 2.
OSCS adulteration of heparin
A detailed description of events related to the OSCS
adulteration of heparin is summarized on the US Food
and Drug Administration (FDA) website [28]. The first
observation of serious adverse events in patients undergo-
ing heparin therapy was made on 19 November 2007 at the
Children’s Hospital in St. Louis, MO, USA, which was
followed by additional cases in January 2008. The marked
increase in allergic reactions following heparin administra-
tion was reported to the Centers for Disease Control and
Prevention (CDC). The CDC alerted the FDA to this
problem on 4 January 2008. Five days later, a connection
between the suspected lots of heparin and Baxter Healthcare
emerged, and Baxter initiated the urgent voluntary recall of
nine lots of single- and multidose heparin vials on 17
January and all of its heparin products on 28 February, when
it stopped heparin production. On 14 February the Chinese
company Changzhou SPL was identified as the source of
contaminated heparin which was spread worldwide, affect-
ing more than ten countries. Besides Changzhou SPL, the
contaminant was traced by the FDA to 11 other Chinese
companies in the heparin API supply chain, contributing to
the extended crisis [28].
The administration of contaminated heparin lots was
associated with the acute, rapid onset of a potentially fatal
allergic reaction [1, 2]. These adverse reactions resulted in
over 200 deaths, which were attributed to hypotension
triggered by anaphylactic shock [1, 2, 6], prompting the
FDA to identify the contaminant while working in
collaboration with scientists in industry and academia. By
5 March 2008, equipped with preliminary data obtained by
the combined use of optical rotation, capillary electropho-
resis (CE), and 1H NMR, the FDA announced that the
contaminant was a “heparin-like” molecule. The following
day the FDA posted protocols for using NMR and CE to
screen heparin batches for the contaminant. After these
safeguards were put into place, the number of adverse
reactions returned to background levels. In a matter of
weeks, the multidisciplinary team led by Ram Sasisekharan
at the Massachusetts Institute of Technology identified and
presented the structure of the contaminant to the FDA. Two
days later, on 19 March, the agency announced that the
contaminant was OSCS, a structurally unique glycosami-
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Fig. 2 Major repeating disaccharide units of heparin-like GAGs: a
CS; b DS; c OSCS. The backbone of DS is not homogeneous; the vast
majority of the uronic acid residues are IdoA, but DS also contains
minor amounts of GlcA. The backbones of CS and OSCS are
homogeneously composed of GlcA. For CS, R1–R4 can be either
sulfonated or unsubstituted
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noglycan with an unnatural sulfonation pattern. The
physicochemical properties of the isolated contaminant
were in good agreement with those of chemically synthe-
sized OSCS [27]. According to our present knowledge,
OSCS is not a natural product arising from animal sources.
Therefore, it must be concluded that this was not a case of
accidental contamination, but that OSCS was intentionally
added to the raw heparin product as an act of purposeful
adulteration.
The detection and the subsequent identification of OSCS
as the heparin contaminant relied heavily on CE and NMR,
especially 13C and multidimensional NMR methods
(Fig. 3). The first information about the contaminant’s
structure was provided by simple 1H and 13C NMR
experiments. In addition to the N-acetyl resonances belong-
ing to both heparin (2.04 ppm) and DS (2.08 ppm), a
known heparin impurity [25], an unusual N-acetyl signal at
2.16 ppm was observed in heparin lots associated with the
adverse events (Fig. 3a). The 13C NMR spectra of
contaminated heparin lots also contained signals at
25.6 ppm and 53.5 ppm indicative of an O-substituted N-
acetylgalactosamine moiety of unknown origin that was
distinctly different from DS (Fig. 3b). The 13C signals in
the range 103–105 ppm suggested a β-glycosidic linkage
between the monosaccharides. The results of homonuclear
(COSY, TOCSY, ROESY) and heteronuclear (HSQC,
HMBC) 2D NMR experiments were consistent with a
structure containing a polymeric repeat of N-acetyl galac-
tosamine linked to glucuronic acid. Though a preliminary
identification of the contaminant was possible by NMR,
conclusive assignment was achieved only after the
enzymatic depolymerization of heparin and DS followed
by the subsequent isolation of the intact OSCS polysac-
charide. Parallel to the enrichment of the contaminant by
enzymatic degradation, alcohol-based selective precipita-
tion and chromatographic separations were also used to
purify the contaminant. Taken together, the results
unequivocally proved the structure of OSCS as a
polymer of the unusual tetrasulfonated disaccharide
composed of 2,3-O-sulfoglucuronic acid and 4,6-O-
sulfo-N-acetylgalactosamine with a 1,3 linkage between
the two sugars and 1,4 linkage between adjacent disac-
charide units. Because OSCS is a semisynthetic polysac-
charide, direct comparison of the NMR spectra of the
isolated material with a synthesized OSCS standard
confirmed the identity of the contaminant [1, 6, 27, 29].
Shortly after the structural studies, a biological investi-
gation was initiated in late March 2008 to find the missing
link between OSCS and the adverse reactions. The high
charge density of OSCS resulted in strong anti-factor IIa
activity, allowing the contaminated sample lots to pass
through the anticoagulation potency screens that were used
to determine heparin efficacy and purity. Highly charged
Fig. 3 NMR spectra of contaminated heparin. a Comparison of
anomeric and acetyl regions of the 1H NMR spectra of standard
heparin, heparin containing natural dermatan sulfate (DS), and
contaminated heparin. b Comparison of the carbonyl (i), sugar (ii)
and N-acetyl (iii) regions of the 13C NMR spectra of standard heparin,
heparin containing natural dermatan sulfate, and contaminated
heparin. Signals due to the contaminant are highlighted by asterisks.
c HSQC spectrum of the contaminated sample overlaid on that of a
control heparin sample. Reprinted from [1] with permission from
Macmillian, copyright 2008
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anionic polysaccharides similar to heparin and OSCS
have also been shown to be potent mediators of the
immune response system, which may explain the severe
anaphylactic response observed upon administration of
the contaminated heparin [2, 6]. A study to determine the
biological link between the presence of OSCS in heparin
and anaphylactic events established that concentrations of
2.5 and 25 μg/mL of OSCS in heparin activated the kinin–
kallikrein pathway and its complement pathways through
the fluid-phase activation of FXII in the coagulation
pathway [3]. Kinin–kallikrein pathway activation results
in the formation of bradykinin peptides. A strong correla-
tion has been reported between the OSCS concentration in
the contaminated heparin and the released bradykinin
concentration [30], which is responsible for the enlarge-
ment of blood vessels and the subsequent drop in blood
pressure.
Identification of OSCS paved the way for the establish-
ment of authentic standards and analytical protocols to
guard against future problems resulting from heparin
contamination by this substance. With the introduction of
an OSCS standard, NMR, HPLC, and CE methods were
quickly developed to screen heparin lots in order to prevent
further exposure of patients to contaminated heparin [31].
To ensure the safety of the heparin supply chain, the FDA
has recommended the further development of additional
physicochemical methods for the analysis of heparin purity
[32].
New analytical methods for heparin impurity analysis
The health crisis created by the intentional adulteration of
heparin stimulated the analytical chemistry community to
rapidly introduce a number of new analytical methods for
heparin impurity analysis. Work in this area continues, and
this special issue contains several innovative new develop-
ments and applications that further advance the methods
available for the identification and characterization of
heparin impurities.
Heparin belongs to one of the most challenging groups
of pharmaceutical agents to analyze and characterize.
Compared to a small drug molecule, the molecular
properties of pharmaceutical heparin have traditionally
been pushed into the background due to its extremely
complex, polydisperse and microheterogeneous structure.
Structural studies on heparin at the molecular level usually
begin with depolymerization of the raw/pharmaceutical
material into smaller oligosaccharide fragments using
enzymatic or chemical methods [33, 34]. The enzymatic
depolymerization of heparin can be achieved by heparin
lyases (classes I, II and III) produced by Flavobacterium
heparinum [35]. Each class has a different substrate
specificity with respect to the uronic acid moiety and
sulfonation pattern recognized, but in all cases the cleavage
of the glycosidic linkage between the glucosamine and
uronic acid residues is accomplished through β-elimination.
This step generates a double bond between the C-4 and C-5
positions of the uronate residue, allowing UV detection of
the generated fragments at 232 nm with an approximate
molar absorption coefficient of 5500 M−1cm−1 [36]. In
chemical reactions that are used to convert heparin to
smaller oligosaccharides, either the oxidative instability of
the polymer is utilized or the enzymatic reaction is
mimicked chemically [22]. The main scope of chemical
depolymerization is the preparation of LMWHs.
The activity of pharmaceutical heparin is specified by
clotting-time assays in the pharmacopoeias. Since OSCS
exhibits anticoagulation activity [27], contaminated heparin
samples passed the whole-blood coagulation screens per-
formed by the manufacturer. Although the bio- and
physicochemical behavior of OSCS is similar to that of
heparin in many ways, there are differences that can be
used to discriminate the impurity from the parent drug.
Previous studies have shown that OSCS is resistant to
heparin lyase degradation [24], which was utilized in a
bioassay developed by Tami et al. [37]. The activity of the
thermostable DNA polymerase from Thermus aquaticus
was used in real-time PCR to detect changes in gene
expression inhibited by heparin [38] which can be
overcome by heparinase enzymes [39]. Because OSCS
blocks polymerase-mediated cDNA amplification in a
manner similar to heparin, a sensitive screening method
was developed to evaluate OSCS contamination [37]. This
method requires as little as 0.6 μg of sample, so it may be a
viable option for screening mass-limited samples such as
heparin-coated devices. A correlation was found between
the degree of sulfonation and the inhibitory effect of other
possible oversulfated GAGs impurities (e.g., oversulfated
heparan sulfate, OSHS, and oversulfated dermatan sulfate,
OSDS), which can promote further application of this
technique. A commercially available heparin enzyme
immunoassay kit can also be used to distinguish highly
sulfated GAGs (including oversulfated heparin) and normal
heparin [40]. The recognition element used in this kit is an
engineered protein showing 100-fold selectivity in binding
to heparin over other GAGs [41]. Although electrostatic
interactions between the polybasic binding site of the
protein and heparin contribute only 28% of the total
binding, competing GAGs with higher charge density bind
to the protein with up to fourfold higher affinities than
heparin. This inexpensive method, initially developed for
the clinical determination of heparin levels in human
plasma, provides a simple tool that can be used in early-
stage production settings for impurity quantitation. There
are several other assays for the quantification of heparin
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and other sulfonated biopolymers, but they are not able to
differentiate components that are present in mixtures unless
additional treatments are applied prior to analysis [42].
In the rapidly growing area of chemical/molecular sensor
development, various novel reporter molecules have been
introduced as heparin sensors [43, 44]. In these applications
the sensory effect is based on charge interactions, so their
specificity is limited. Among the biosensors, potentiometric
detection of polyanionic species (such as OSCS) has been
achieved using modified polymer membranes with anion-
exchange capacity [45]. As with previous methods, this
simple approach gives a reproducible response to highly
charged impurities. Since the initial report of this biosensor,
additional studies have been performed to clarify the
quantitation procedure [46].
To ensure the identity and quality of critical drugs such
as heparin, orthogonal and complementary methods to
those employed in the pharmacopoeia should also be
applied, including NMR, Raman, and near-infrared spec-
troscopy (NIR) [4, 47]. An advantage of both NIR and
Raman spectroscopy is that they can be used to characterize
solid heparin samples and detect OSCS contamination
above 1% [48]. A nondestructive NIR method has been
extended beyond impurity analysis as a potential tool for
heparin potency determination [49].
Efforts are also being made to develop quick and cheap
thin layer chromatography (TLC) methods to characterize
GAGs [50]. It has been shown recently that TLC can be
used to determine the size and purity of GAG-derived
oligosaccharides, to analyze the activities of polysaccharide
lyases acting on GAGs, and to monitor the preparation of
GAG-derived oligosaccharides [51]. At the current time,
this method is only able to separate oligosaccharides
bearing low net charges.
NMR spectroscopy
NMR played a decisive role in the structure determination
of OSCS during the heparin crisis, although the exception-
ally high concentration of OSCS in the adulterated samples
likely contributed to its successful identification by this
method. The complete 1H NMR assignment of OSCS has
been reported in several recent publications [1, 31, 52, 53]
and in the original work by Maruyama et al. [27]. It is also
important to note that Holzgrabe et al. published 1H NMR
spectra of heparin in 1998 which already contained the
resonances of OSCS [54]. In addition to the 1H and 13C
NMR spectra, the heteronuclear HSQC and HMBC experi-
ments were important for the conclusive molecular level
characterization of OSCS (Fig. 3c). Signals associated with
the characteristic OSCS moieties are easily detectable in the
HSQC spectrum of OSCS-contaminated heparin (Fig. 4).
Due to its high sensitivity to even minor structural
variations, 1H NMR spectroscopy has been used previously
to detect variations in the chemical composition of heparin
[25, 55, 56], low molecular weight heparins [57], heparin-
derived oligosaccharides [58, 59] and as a screening tool for
GAG impurities [25, 60]. As 1H NMR has also been
recommended by the FDA as one of the analytical
techniques for rapidly screening OSCS, intense efforts are
being made to improve the NMR-based characterization of
heparin API. To obtain a satisfactory NMR spectrum for
correct identification, several factors should be considered.
As demonstrated previously, the chemical shift of the OSCS
N-acetyl methyl signal is counterion type and concentration
dependent; it varies linearly from 2.13 ppm to 2.18 ppm with
increasing amounts of Ca2+ until reaching a saturation point
of four Ca2+ per tetrasulfonated disaccharide unit [61].
Paramagnetic transition metal ions, present as production
residuals, can cause line broadening through paramagnetic
relaxation enhancement, even within the range of allowed
quantities [62]. Especially Mn2+ was found to present the
most pronounced effect on the heparin iduronic acid H1
(5.22 ppm) and H5 (5.42 ppm) protons and the OSCS
methyl protons, the crucial signal for OSCS quantification.
Filtering the solution through a cation exchange resin prior to
measurement or adding 300 μg EDTA per gram of heparin
can eliminate the unwanted broadening [62].
Acquiring spectra at elevated temperatures can improve
the 1H resonance line shape of GAG solutions [63].
Fig. 4 HSQC spectrum of heparin containing 10% (w/w) OSCS
prepared using a 20 mg/mL D2O solution of the USP system
suitability standard at pD 6.6 and 298.2 K. To improve the line shape,
1% EDTA-d16 was added. The spectrum was acquired using 32 scans
per increment with 2560 and 512 data points in F2 and F1,
respectively, using a 600 MHz NMR equipped with a broadband
inverse probe. The polarization transfer delay was set using a 1JC–H
coupling value of 155 Hz. The spectrum was referenced to internal
TMSP. The characteristic OSCS signals for GalNAc4S6S and
GlcA2S3S are labeled as A and U respectively
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Measuring spectra at 333 K (or even 353 K) enables clear
isolation of the H5 proton of the sulfonated iduronic acid
residue from other proton signals in the fingerprint region,
including the water/HDO resonance due to its temperature-
induced upfield shift [64]. Caution should be applied when
taking measurements using unbuffered heparin solutions,
which can result in pH-dependent chemical shift differences
for the carboxylate-adjacent H5 proton of the uronic acid
residue [53].
Low-level contaminant peaks can be masked by the
heparin 13C satellite peaks, and in these cases 13C
decoupling is recommended to discriminate the satellite
peak from the contaminant [65]. Although it can be difficult
to detect certain GAG impurity signals by visual inspection
of the 1H survey spectrum, multidimensional NMR can
easily detect and distinguish between analogous sulfonated
polysaccharides [66]. To obtain more contaminant-specific
signals from the crowded fingerprint region and improve
the reliability of impurity identification, 2D NOESY can
provide a highly informative 1H fingerprint [67].
The accurate quantification of 1H NMR signals requires
a high-quality spectrum, which can typically be achieved
using a high magnetic field (≥500 MHz), optimum solution
conditions, and appropriate NMR parameters [53]. Beyer
and coworkers have shown that even when using 300 or
400 MHz NMR spectrometers, the OSCS LOD can be as
low as 0.1% [63] These authors analyzed over 100 heparin
API samples using the standard addition method and
monitoring the N-acetyl region. They developed a routine
1H NMR-based screening for heparin API, quantified both
OSCS and DS, and proved the lack of correlation between
these signals. In addition to quantifying OSCS and DS,
Beyer et al. also reported other impurities that are present in
varying amounts in pharmaceutical heparin, including
methanol, ethanol and acetate [63]. In a subsequent study,
this group also scrutinized the German heparin market and
analyzed 145 representative samples from 2008 [68]. The
samples tested by 1H NMR were found to contain DS
(51%) and OSCS (19%), as well as process-related
impurities such as ethanol, methanol, acetone, formic acid
and acetate in considerable amounts. As these process
impurities remain undetectable by CE and LC methods, it is
anticipated that NMR may be more widely exploited in
future pharmacopoeias. Keire et al. have also reported a
0.1% LOD for OSCS on a 500 MHz instrument using
25 mg/700 μL heparin solutions [69]. This group has also
identified additional native and oversulfated GAGs as
possible economically motivated adulterants based on their
characteristic chemical shifts in the N-acetyl and 3.0–
6.0 ppm region [70]. CSA, DS, OSCS and OSDS showed
unique signal patterns when spiking the heparin sample,
while HS, OSHS and oversulfated heparin were found to be
difficult to identify [70].
Diffusion NMR experiments correlate the rate of decay
of NMR resonances with their translational diffusion
coefficients, which are related to molecular properties such
as size, shape, and charge. Diffusion NMR can be a very
useful method for mixture analysis, often allowing the
noninvasive separation of resonances due to different
mixture components [71]. The first report that employed
diffusion NMR to characterize heparin solutions, from
Kellenbach and coworkers [72], used pulsed-field gradient
longitudinal encode-decode (PFG-LED) experiments to
identify signals of low molecular weight impurities in a
synthetic heparin pentasaccharide solution. Because of the
large difference in size between the synthetic heparin
pentasaccharide and its impurities, simple “gradient on/
off” experiments were capable of discriminating between
the components in the synthesis solution.
Shortly following the identification of OSCS as the
heparin adulterant, Sitkowski and coworkers investigated
the utility of DOSY NMR as a routine screening method for
OSCS in LMW and unfractionated heparin [73]. DOSY is a
pseudo-2D NMR experiment that correlates the calculated
diffusion coefficient with the NMR chemical shift. Because
the chemical shifts of the N-acetyl resonances of heparin,
DS, and OSCS are well resolved, the DOSY plots obtained
by Sitkowski et al. could resolve the diffusion coefficients
of OSCS and DS from both LMW and unfractionated
heparin. They also observed that in mixtures containing
both LMW and unfractionated heparin, the components
could not be resolved on the basis of diffusion, and the
diffusion coefficient measured for heparin was a weighted
average of both components. In a recent study by the same
group, diffusion NMR was used for the separation and
characterization of contaminants in pharmaceutical heparin
[74]. These authors noted resonances of currently uniden-
tified contaminants which produced diffusion coefficients
that were different from those observed for heparin, DS,
and OSCS.
In addition to the contamination of heparin with OSCS
and DS, the chemical modification of heparin during the
manufacturing process could be another source of heparin
impurities, such as those introduced by O-acetylation [4].
Such impurities are likely to be present at low levels and
can be challenging to identify due to their structural
similarity to heparin. A novel heteronuclear NMR experi-
ment, HEHAHA, introduced by Jones and Bendiak [75],
has been used to characterize the primary structures of
oligosaccharides as well as to determine positions of
modification. This experiment uses doubly 13C-labeled
acetyl groups to establish correlations between protons on
the sugar rings and O-acetyl moieties. A selective version
of this experiment, SHEHAHA, accomplishes magnetiza-
tion transfer between the carbonyl 13C and the proximal
proton on the sugar ring while suppressing proton–proton
Analysis and characterization of heparin impurities 533
TOCSY relay to the other sugar ring protons, allowing
assignment of the location of the O-acetyl group [75, 76].
Electrophoretic methods
Polyacrylamide gel electrophoresis (PAGE)
Fractionation of highly charged macromolecules generally
requires successive use of several separation steps, one
sensitive primarily to molecular size, and another based
mainly on net charge. PAGE provides a versatile method
for the separation and physicochemical characterization of
molecules by exploiting differences in size, conformation
and charge [77]. The utility of this technique in GAG
oligosaccharide sequencing has been demonstrated [78–80].
For oligosaccharide purification and isolation, native PAGE
has been used, but the recovery of the separated compo-
nents on the micropreparative scale was difficult, and the
purity of the isolated sample was insufficient for structural
studies by NMR and MS [81]. In contrast, native
continuous elution PAGE provides high-resolution separa-
tion of GAG-derived oligosaccharides over a large molec-
ular weight range, and the gel-eluted oligosaccharides are
amenable to structural characterization [82]. As a comple-
mentary screening technique to 1H NMR, PAGE was
utilized in a comprehensive analysis of 31 heparin samples
prepared from 1941 through 2008 [83]. Nitrous acid
depolymerization of the heparin API followed by PAGE
analysis gave LOD values for heparin impurities ranging
from 0.1 to 5%.
PAGE was also used to characterize the sensitivity of
OSCS to different depolymerization processes used in
LMWH production [24]. On the basis of this analysis,
OSCS was found to be sensitive to base-catalyzed β-
eliminative cleavage and H2O2 treatment. Oxidative depo-
lymerization by H2O2 converted OSCS to monosaccharides
at pH 2 (a more efficient depolymerization compared to
heparin), while longer oligosaccharides were observed at
pH 5 and pH 7. The oversulfated impurity was resistant to
heparin lyase I treatment, and due to its structural features
both nitrous acid (due to the lack of a nitrous acid sensitive
N-sulfo group) and periodate (due to lack of a vicinal diol
moiety) failed to degrade OSCS [24]. PAGE analysis of
OSCS-contaminated low molecular weight heparins suc-
cessfully detected OSCS among other possible impurities
following nitrous acid treatment.
Capillary electrophoresis (CE)
Given the polyanionic nature of GAGs, capillary electro-
phoresis is one of the best separation techniques to analyze
highly charged polysaccharides [84]. The advantages of CE
methods over other chromatographic approaches are the high
number of theoretical plates, rapid analysis time, and low
sample consumption. Compared to liquid chromatographic
methods, no organic solvents or additives are necessary, so
this method is more environmentally friendly. The possibility
of on-line coupling with MS [84, 85] and NMR as detectors
gives the potential to obtain unique structural information.
As crude GAG polymers lack strong UV chromophores, it is
difficult to detect them directly by UV measurements.
Indirect detection of GAGs in CE overcomes this limitation,
but it can be difficult to find a suitable background
electrolyte which meets all of the necessary criteria [86].
Depending on the approach used, the controlled degradation
of the GAG biopolymers can also improve their detection.
For example, enzymatic depolymerization or chemical
degradation under alkaline conditions introduces a chromo-
phore that allows sensitive UV detection and quantitative
determination. Alternatively, the oligosaccharides can be
chemically derivatized, mainly at the reducing end of the
sugar, converting them to analytes suitable for UV or the
more sensitive fluorescence detection.
The electrophoretic behavior of heparin-derived oligo-
and disaccharides has been intensively studied for the past
two decades, with the first CE application for both intact
and depolymerized GAGs reported in the 1990s [87, 88].
Among the first steps in the evolution of CE methods was
the recognition of the advantage of acidic buffers over the
previously applied basic, SDS-containing background
electrolytes [89] and the resolving power of reversed-
polarity separations [90]. In the case of reversed polarity,
the sample is introduced at the negative end of the capillary
and migrates in the opposite direction to the electroosmotic
flow (EOF). At low pH, the EOF is naturally low, and as
phosphate buffer is well known to coat the capillary surface
[91], good reproducibility of migration times is obtained
through well-controlled EOF. The pH selected for reversed
polarity CE separations of GAG-derived compounds is
typically around 3.5–4, near the pKa values of the uronic
acid carboxylate groups. The differential effective charge
resulting from the subtle effects of structure on carboxylic
acid pKa values allows the resolution of oligosaccharides
which would otherwise have very similar migration times
[92]. Further developments aimed at improving the sensi-
tivity of detection using laser-induced fluorescence [93] and
electrospray ion trap mass spectrometry [94] have been
reported. For low molecular weight heparins, CE offers the
possibility of fingerprinting these biopolymer mixtures,
which is especially useful for assessing product identity,
quality and variability [95].
Since the OSCS adulteration event, there has been
growing interest in CE applications for the rapid screening
of heparin, as capillary electrophoresis is one of the
techniques recommended by the FDA. The intense effort
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to identify OSCS in contaminated samples led to a robust,
validated CE method which was quickly incorporated into
the USP monograph. The basis for this initial CE separation
were previously reported phosphate buffer-based reversed-
polarity methods [96, 97]. This so-called “emergency
method,” in conjunction with NMR, helped to identify
and remove suspect heparin lots from the market. However,
the downside of the emergency CE method is its relatively
high LOD for OSCS, estimated at between 1 and 5% of
total heparin, far from the expected 0.1%. Also, as shown in
Fig. 5a, only partial separation of OSCS and heparin could
be achieved; the contaminant appeared as a leading edge
peak that was only partially resolved from the broad peak
associated with heparin. In order to reach the desired low
limit of detection and separation resolution, and to extend
the method to other possible impurities such as DS and
heparan sulfate, Wielgos and coworkers have optimized
and improved the CE separation protocol [98]. Although
this method fulfills all the necessary criteria for a sensitive,
selective, robust and reproducible separation method, as
illustrated by the electropherograms shown in Fig. 6, the
capillary used in this separation fits only the Agilent CE
instrument. Shortly after this publication, a similar simple
methodology appeared demonstrating the applicability of
the method on generic CE equipment [99]. Method
development in both cases started with the USP-adapted
version of the FDA method using a 50 μm I.D. capillary
and 36 mM phosphate buffer (pH 3.5).
In this system, the migration order of the GAG
components is determined largely by their charge; OSCS
has the fastest migration, followed by heparin, with the
least-charged component, dermatan sulfate, migrating most
slowly, as shown in Fig. 5a. During the optimization of
these CE methods, the concentration of the background
electrolyte (BGE) was found to be crucial to an effective
separation. Increasing buffer concentration relative to that
used in the initial USP emergency method led to the
following improvements: (i) better sample stacking and
sharpening of the OSCS peak as a result of the larger
difference in conductivity between the running buffer and
the analyte; (ii) improved resolution; (iii) higher current and
Joule-heating effects which required the use of smaller
(25 μm) I.D. capillaries; (iv) application of BGEs below pH
3.5, and; (v) injection of large sample volumes of
concentrated samples, which allowed these methods to
reach a reasonably low LOD (0.05% or even less) for
OSCS (Figs. 5b and 6). A crucial parameter to allow high-
molarity buffers and achieve full separation is the replace-
ment of sodium ions by lithium [98] or Tris [99], as these
ions contribute less to the BGE conductance but still
provide the same ionic strength. There are certainly other
parameters besides the aforementioned ones that influenced
the separation (such as the applied voltage, capillary length
and temperature, injection parameters), but their optimum
values are predominantly empirically determined.
The main advantage of CE for heparin impurity analyses
is the rapid analysis time, allowing high-throughput
screening of the QC samples. Using a shortened capillary
and replacing sodium ions by the lower mobility lithium led
to a much shorter and better separation, with a LOD well
below 0.1% [98], as can be seen in Fig. 6. Another
innovative approach is the anthranilic acid (AA) derivati-
zation and CE separation of the GalN and GlcN hexos-
amines of OSCS and heparin, respectively, following acidic
hydrolysis [100]. An advantage of this approach is that the
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Fig. 5 a CE-UV electropherogram of OSCS-contaminated heparin
(10 mg/ml) using the FDA emergency method. (50 μm capillary I.D.,
36 mM sodium phosphate pH 3.5 BGE, capillary temperature 25 °C,
12 s sample injection at 0.5 psi; −30 kV voltage.) The unresolved
peaks are OSCS, heparin and DS, respectively, according to their
decreasing mobility. b CE-UVof OSCS-contaminated heparin (10 mg/
ml) using the optimized method. (25 μm capillary I.D., 850 mM Tris
phosphate pH 3.0 BGE, 60 cm total capillary length, capillary
temperature 35 °C, 24 s sample injection at 2.0 psi; −30 kV voltage.)
Reprinted from [99] with permission from Elsevier
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AA derivatives have similar molar absorptivities, allowing
direct quantitation from the electropherogram. The urgent
need for but lack of an appropriate CE method for heparin
impurity analysis in the pharmacopoeias evokes further
method refinements [101], but even with these limitations
CE has become an alternative method to NMR for reliable
heparin quality assurance.
Chromatography and hyphenated techniques
This section discusses chromatographic methods developed
for the analysis of the heparin impurities OSCS and DS. A
detailed discussion of the application of chromatographic
separations for heparin structural characterization is beyond
the scope of this paper, and has been recently reviewed [5].
HPLC is the most prevalent technique in analytical labora-
tories and is frequently used in pharmacopoeial monographs.
A broad range of HPLC techniques are available for heparin
analysis, the majority of which utilize anion-exchange or
reversed-phase ion-pair separations. Strong anion-exchange
(SAX) HPLC methods have been used for the isolation,
purification and oligosaccharide mapping of depolymerized
heparin [102–104]. The separation of oligosaccharide
species by charge using salt gradient elution is convenient
and easy to perform, so SAX-HPLC is a plausible
technique for heparin impurity analysis. Silica-based SAX
columns with quaternary ammonium groups were shown to
be unsuitable for persistent application due to poor stability
and retention time reproducibility [31, 102]. Therefore,
Trehy et al. used a polymeric SAX column for heparin
impurity separations [31]. Using a linear gradient from
0.125 M to 2.5 M NaCl in pH 3 buffered mobile phase at
35 °C, UV detection at 215 nm and a constant 0.8 mL/min
flow rate, this SAX separation gave LODs for OSCS and
DS of 0.03% and 0.1%, respectively. A slight modification
of the sample preparation protocol, dissolving 100 mg
sample in 1 mL of the 2.5 M NaCl eluent buffer, gave an
even better LOD (0.02%) and LOQ (0.09%) for OSCS [69].
This SAX-HPLC method is a more sensitive method of
detecting OSCS in crude heparin than NMR and is also
able to separate heparin from other contaminants such as
HS, DS, their oversulfated derivatives (e.g., OSHS, OSDS)
as well as oversulfated heparin (OSH) [70].
Weak anion-exchange (WAX) HPLC methods have also
been reported for OSCS [105, 106]. Hashii et al. showed
that replacement of NaCl in the elution buffer with alkali
perchlorates resulted in better peak symmetry and less
baseline drift using UV detection, producing an LOD for
OSCS that was comparable with the previously described
SAX method [106]. Because of the important role played
by NMR spectroscopy in the identification of OSCS as a
heparin contaminant, our group explored the use of WAX
HPLC-NMR for the separation and identification of heparin
and its impurities DS, CSA, and OSCS [105]. Using WAX
chromatography, the intact GAGs were separated using a
salt gradient from 0.1 M to 1.0 M NaCl at a solution pD of
10.25 with UV detection at 215 nm and on-flow 1H NMR.
Figure 7 shows the UV chromatogram (A) and on-flow
NMR spectrum (B) for the separation of heparin and OSCS.
Although the on-flow NMR spectra are noisy, stop-flow
HPLC-NMR can be used to improve the S/N of the spectra
and for 2D NMR experiments, which are often necessary
for contaminant identification. We also demonstrated that
by holding the NaCl concentration below 0.8 M, OSCS can
be near-quantitatively trapped on the WAX column while
heparin is directed to waste, allowing on-column concen-
tration through multiple injections. Peak trapping of OSCS
provided a route to the on-line concentration of the
contaminant, presenting a more concentrated sample for
1H NMR identification and structural characterization. This
work demonstrates that when unexpected peaks are
encountered in the routine screening of samples by LC-
UV, WAX-NMR can be exploited for the rapid identifica-
tion and structural elucidation of new or novel impurities.
Size-exclusion chromatography (SEC) can also be used
to detect and quantify OSCS in contaminated samples. Due
to its resistance to heparinase I digestion, OSCS contam-
inants remain intact after depolymerization of unfractio-
nated heparin and enoxaparin samples [52]. SEC results
indicated that the mean molecular weight of OSCS in
recalled heparin batches was 16.8 kDa [52].
Reversed-phase ion-pair (RPIP) HPLC is a promising and
increasingly popular method for the separation of heparin
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Fig. 6 High-speed CE separation of heparin, OSCS and DS. (25 μm
capillary I.D., 600 mM lithium phosphate pH 2.8 BGE, temperature
20 °C, 600mbs injection and −14 kV voltage.) Reprinted from [98]
with permission from Elsevier
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oligosaccharides [107, 108]. Several studies have demonstrat-
ed the amenability of RPIP-HPLC and UPLC to on-line MS
detection, greatly improving the sensitivity and amount of
structural information that can be obtained [109–112].
Following heparinase cocktail digestion of control and
OSCS-contaminated heparin samples, RPIP-HPLC was used
to record chromatograms for which the heparin di-, tri-, and
tetrasaccharide peaks were integrated. The contaminated
samples contained significantly reduced peak areas compared
with the controls, indicating that the contaminant was
heparinase resistant, and aiding its identification as OSCS [1].
Future prospects
Prompted by the need to identify OSCS in contaminated
heparin lots, a wealth of analytical methods have been
developed for the quality assurance and rapid identification
of contaminants in unfractionated and LMW heparin. Heparin
is among the few remaining pharmaceutical agents isolated
from animal sources, which along with its inherent heteroge-
neity contributes to challenges in quality assurance. Although a
synthetic heparin pentasaccharide—fondaparinux—is current-
ly available, its market share is relatively low. Fondaparinux is
used clinically for treatment of deep-vein thrombosis and
pulmonary embolism, but its urinary excretion precludes its
use for dialysis patients. On the horizon are higher molecular
weight synthetic heparin drugs, the development of which will
depend on improved synthetic methods, or alternatively
bacterial expression systems that can produce effective heparin
substitutes. Until reliable synthetic, semisynthetic, or bacteri-
ally expressed products are available for all clinical applica-
tions of heparin, the need for robust, efficient and sensitive
analytical methods for heparin impurities will remain.
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Fig. 7 Weak anion exchange separation of a 40 mg/mL heparin and OSCS sample using the Asahipak NH2P50E amino-bonded column with UV
(a) and on-flow 1H NMR (b) detection. Reprinted from [105] with permission from the American Chemical Society, copyright 2009
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